Manning & Napier Group’s NVO Holdings & Trades

First Buy
Q2 2025
Duration Held
2 Quarters
Largest Add
Q2 2025
+204,174 shares
Current Position
182,201 shares
$10.11 M value

Manning & Napier Group's NVO Position Overview

Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 182.2K shares of Novo Nordisk A/S (NVO) worth $10.11 M, representing 0.13% of the portfolio. First purchased in 2025-Q2, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Manning & Napier Group has initiated a new position in NVO, representing a fresh investment thesis on this company. Largest reduction occurred in Q3 2025, reducing 22.0K shares.

Analysis based on 13F filings available since 2013 Q2

Manning & Napier Group's Novo Nordisk A/S (NVO) Holding Value Over Time

Track share changes against reported price movement

Quarterly Novo Nordisk A/S (NVO) Trades by Manning & Napier Group

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2025 +204,174 New Buy 204,174 $69.02
Q3 2025 -21,973 Reduce 10.76% 182,201 $55.50

Manning & Napier Group's Novo Nordisk A/S Investment FAQs

Manning & Napier Group first purchased Novo Nordisk A/S (NVO) in Q2 2025, acquiring 204,174 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Manning & Napier Group has held Novo Nordisk A/S (NVO) for 2 quarters since Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Manning & Napier Group's largest addition to Novo Nordisk A/S (NVO) was in Q2 2025, adding 204,174 shares worth $14.09 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 182,201 shares of Novo Nordisk A/S (NVO), valued at approximately $10.11 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.13% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Manning & Napier Group's peak holding in Novo Nordisk A/S (NVO) was 204,174 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.